Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.
Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.
复制标题
胰腺癌的联合治疗：基于抗 PD-(L)1 的策略
DOI：
10.1186/s13046-022-02273-w
复制
发表时间：
2022-02-09
期刊：
影响因子：
--
通讯作者：
Bai X
中科院分区：
文献类型：
--
作者：
Liu L;Huang X;Shi F;Song J;Guo C;Yang J;Liang T;Bai X
胰腺癌的死亡率是所有恶性肿瘤中最高的，5年总生存率为5-10%。以针对程序性细胞死亡蛋白1或其配体1 （anti-PD-(L)1）的阻断抗体为代表的免疫疗法在许多恶性肿瘤中取得了显著的成功。然而，由于肿瘤微环境具有免疫抑制作用，抗pd -(L)1在胰腺癌中的治疗效果远未达到预期。为了解决这一根本性问题，在临床前和临床研究中，化疗、放疗、靶向治疗甚至免疫治疗本身都分别尝试与抗pd -(L)1联合使用。本文以胰腺癌治疗为重点，收集了目前基于抗PD-(L)1的联合用药策略，强调了累积联合用药可能存在的不良反应，并进一步指出了未来联合用药的优化方向，包括针对PD-(L)1的翻译后修饰和提高治疗精度。
Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1), has achieved remarkable success in a number of malignancies. However, due to the immune-suppressive tumor microenvironment, the therapeutic efficacy of anti-PD-(L)1 in pancreatic cancer is far from expectation. To address such a fundamental issue, chemotherapy, radiotherapy, targeted therapy and even immunotherapy itself, have individually been attempted to combine with anti-PD-(L)1 in preclinical and clinical investigation. This review, with a particular focus on pancreatic cancer therapy, collects current anti-PD-(L)1-based combination strategy, highlights potential adverse effects of accumulative combination, and further points out future direction in optimization of combination, including targeting post-translational modification of PD-(L)1 and improving precision of treatment.